Recurrent Childhood Acute Lymphoblastic Leukemia Active Not Recruiting Phase 2 Trials for DB00688 (Mycophenolate mofetil)

Back to Recurrent Childhood Acute Lymphoblastic Leukemia
IndicationStatusPhase
DBCOND0028597 (Recurrent Childhood Acute Lymphoblastic Leukemia)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01529827Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTreatment
NCT00040846Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesTreatment
NCT00036738Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or NilotinibTreatment
NCT00089011Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerTreatment
NCT00118352Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerTreatment